We love sharing our 5-Minute interviews with our vast community, and this latest one with Roya Niki Hugosson, Strategic Account Manager, ISV, Amazon Web Services, was captured at our GraphConnect event in Austin over the summer. We think you’ll enjoy learning more about how AWS works with Neo4j, and hearing some of Roya’s own thoughts on what she sees for the future of graph databases. Enjoy!
Please introduce yourself.
Roya Niki Hugosson: I’m Roya Niki Hugosson from AWS, Amazon Web Services, and I am a Strategic Account Manager at AWS.
Can you tell us about AWS’s partnership with Neo4j?
Roya Niki Hugosson:Of course. So the partnership started a couple of years ago and it has developed and evolved during these years. But we do have a Better Together story at this point, which is great.
So as a partner to Neo4j, we help them in different sales motions and we go to market together. We do different types of workshops based on different use cases that Neo4j has. For example, fraud detection, going together for financial services institutions or for pharma use cases. We have worked during the past two years on those use cases quite a lot together.
What have been the most surprising results you’ve seen from using Neo4j?
Roya Niki Hugosson:I think I mostly focus on FinTech and financial services at AWS, so most of the results I’ve seen come from fraud detection and customers trying to do the same thing on their own and not succeeding.
And then, we went together with Neo4j and told this Better Together story. The customers started using it and the results that they saw – in much less time with much less resources – is mainly the most surprising, for me at least as well as for the customers. Speed and cost, they are important and that’s what customers can get with Neo4j’s graph.
What do you think is in store for the future of graphs?
Roya Niki Hugosson: Oh, many things, actually. Everything from what we talked about with fraud detection, but also more positive impacts. Internet of Things, IoT connected devices, but also in pharma, developing new medicine, new vaccines. And I think that is quite exciting and we will see more and more of that in the future.
Download the White Paper